Presentation is loading. Please wait.

Presentation is loading. Please wait.

Helen Barraclough, MSc, Ramaswamy Govindan, MD 

Published byClementine Hines Modified over 5 years ago

Similar presentations

Presentation on theme: "Helen Barraclough, MSc, Ramaswamy Govindan, MD "— Presentation transcript:

1 Biostatistics Primer: What a Clinician Ought to Know: Subgroup Analyses 
Helen Barraclough, MSc, Ramaswamy Govindan, MD  Journal of Thoracic Oncology  Volume 5, Issue 5, Pages (May 2010) DOI: /JTO.0b013e3181d9009e Copyright © Terms and Conditions

2 FIGURE 1 What is an interaction test? In this hypothetical example, there are two treatment (Tx) arms in the clinical trial: A and B. There are also two levels of the subgroup of patients defined by the baseline characteristic of gender: males and females. The regression lines linking the circles and squares represent the efficacy of treatment A and B, respectively, for overall survival (as estimated by the log hazard from the Cox Proportional Hazards Model). The log hazard estimates the log risk of death. Hence, the higher the regression line, the higher the risk of death. The treatment effect is illustrated by an arrow in each level of the subgroup (which in this example is the log HR[Tx A vs Tx B]). If the regression lines are parallel, there is no interaction between treatment and gender (A). Hence, the treatment effect in males is the same as in females. However, if the regression lines are not parallel (B and C), there is a statistically significant interaction between treatment and gender. Thus, the treatment effect in males is significantly different to that observed in females. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d9009e) Copyright © Terms and Conditions

3 FIGURE 2 Forest plot. Forest plot are commonly used to graphically present subgroup analyses results. Above is a hypothetical result corresponding to the qualitative interaction example described in Figure 1C. The diamond represents the point estimate of the HR(Tx A vs Tx B) and the horizontal lines the 95% confidence intervals. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d9009e) Copyright © Terms and Conditions

4 Journal of Thoracic Oncology 2010 5, 741-746DOI: (10. 1097/JTO
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d9009e) Copyright © Terms and Conditions

5 Journal of Thoracic Oncology 2010 5, 741-746DOI: (10. 1097/JTO
Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e3181d9009e) Copyright © Terms and Conditions

Download ppt "Helen Barraclough, MSc, Ramaswamy Govindan, MD "

Similar presentations

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Thomas F. O’Donnell, MD, Joseph Lau, MD  Journal of Vascular Surgery 

Thomas F. O’Donnell, MD, Joseph Lau, MD  Journal of Vascular Surgery 
Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis  Lama Sakr, MD, MSc, FRCPC, David Small,

Phenotypic Heterogeneity of Potentially Curable Non–Small-Cell Lung Cancer: Cohort Study with Cluster Analysis  Lama Sakr, MD, MSc, FRCPC, David Small,
Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001.

Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer  Sarah Burdett, MSc,
Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Do higher-risk patients benefit from off-pump coronary artery bypass grafting? Evidence from an ecologic analysis of randomized trials  Oliver Kuss, PhD,

Do higher-risk patients benefit from off-pump coronary artery bypass grafting? Evidence from an ecologic analysis of randomized trials  Oliver Kuss, PhD,
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
George E. Kikano, MD, Marie T. Brown, MD  Mayo Clinic Proceedings 

George E. Kikano, MD, Marie T. Brown, MD  Mayo Clinic Proceedings 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer  Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial  Daniel H. Solomon, MD, MPH, M. Elaine.

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial  Daniel H. Solomon, MD, MPH, M. Elaine.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google